La FDA ha aprobado el uso de la inmunoterapia con células T reguladoras alogénicas, HSPC y T-cell-vldq, para el tratamiento de neoplasias hematológicas en adultos mediante trasplante de células madre hematopoyéticas de donante compatible.
La extensión .gov indica que se trata de un sitio web oficial.
Contenido completo del articulo
FDA approves allogeneic regulatory T cell-based immunotherapy with HSPC and T cells-vldq for use in matched donor hematopoietic stem cell transplantation for adults with hematologic malignancies
Preguntas frecuentes
Which products are related to this article?
No strongly related product has been identified yet. The match updates automatically when the article or catalog changes.
How can I view the medicines discussed in this article?
Use the related product cards below the article to review available specifications, prices, product information, and reviews.
Does this article replace advice from a doctor or pharmacist?
No. This content is for general information and health education only. Follow the prescription and individual guidance provided by qualified healthcare professionals.
